CAS |
No.3519-82-2 |
英文名称 |
INCA-6 |
分子式 |
C20H12O2 |
分子量 |
284.31 |
溶解性 |
Soluble in DMSO ≥0.1mg/mL(Need ultrasonic) |
纯度 |
≥98% |
外观(性状) |
Solid |
储存条件 |
Powder: -20℃,2 years |
MDL |
MFCD00226933 |
SMILES |
C1=CC=C2C3C4=CC=CC=C4C(C2=C1)C5=C3C(=O)C=CC5=O |
InChIKey |
GCHPUOHXXCNSQL-UHFFFAOYSA-N |
InChI |
InChI=1S/C20H12O2/c21-15-9-10-16(22)20-18-12-6-2-1-5-11(12)17(19(15)20)13-7-3-4-8-14(13)18/h1-10,17-18H |
PubChem CID |
230748 |
靶点 |
NFAT |
通路 |
Immunology & Inflammation |
背景说明 |
INCA-6是一种细胞渗透性 NFAT 抑制剂。INCA-6 特异性阻断 NFAT底物靶向钙调神经磷酸酶位点,是 calcineurin (CN)-NFAT 信号传导的有效抑制剂。 |
生物活性 |
INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling[1][2][3]. |
In Vitro |
INCA-6 (5 μM; for 24-hour) prevents transient outward K+ current (Ito) downregulation in 3-Hz cells[1].Pre-treatment of BV-2 cells with INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in BV-2 cells. INCA-6 also inhibits ATP-induced CXCL2 expression in rat primary microglia[2]. INCA-6 (5 μM) reduces SERCA2 transcript levels as well as protein expression, in the absence or in the presence of thapsigargin (TG)[3].INCA-6 (1.0 and 2.5 μM; 24 hours ) treatment significantly decreases both VEGF and serum-induced human retinal microvascular endothelial cells (HRMEC) proliferation, but does not affect baseline proliferation[4].Cell Proliferation Assay[4]Cell Line:Human retinal microvascular endothelial cells;Concentration:0.5, 1.0, or 2.5 μM;Incubation Time:24 hours;Result:Significantly inhibited VEGF-induced proliferation at 1.0 and 2.5 μM concentrations. |
In Vivo |
INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR)[4].Animal Model: Rats bearing OIR model[4];Dosage:2.5, 5.0, or 25.0 μM;Administration:Intravitreal injection on days 14(0) and 14(3);Result:Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations. |
数据来源文献 |
[1]. Ling Xiao, et al. Mechanisms underlying rate-dependent remodeling of transient outward potassium current in canine ventricular myocytes. Circ Res. 2008 Sep 26;103(7):733-42. [2]. Miho Shiratori,et al. P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem. 2010 Aug;114(3):810-9. [3]. Anand Mohan Prasad, et al. Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H173-80. [4]. Colin A Bretz, et al. The role of the NFAT signaling pathway in retinal neovascularization. Invest Ophthalmol Vis Sci. 2013 Oct 25;54(10):7020-7. |
规格 |
1mg 5mg 10mg 25mg |
单位 |
瓶 |